Phase 3 Tuberculosis Trial, Recruiting NCT04147286 Sponsor: University of Cape Town Condition: Tuberculosis
Back to Tuberculosis

Phase 3 Tuberculosis Trial, Recruiting

NCT04147286
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have read and signed a consent form before any screening, and you are willing to have an HIV test
  • You are between 18 and 65 years old and weigh between 50 kg (110 lbs) and 90 kg (198 lbs)
  • Your TB treatment worked well and your sputum (mucus) test came back negative at week 16 of treatment
  • You have completed a full 24-week (6-month) course of standard TB treatment
  • You have been officially declared "cured" of TB by the South African TB Control Program
  • If you are HIV-positive: you have been on HIV treatment (antiretroviral therapy) for at least 12 weeks and your HIV viral load is undetectable within the last 30 days
  • If you are HIV-positive: your immune cell count (CD4) is above 350 cells/µL within the last 30 days
  • Your liver enzyme levels (AST and ALT) are within an acceptable range based on a blood test taken within the last 30 days
  • Your kidney function level (creatinine) is within an acceptable range based on a recent blood test
  • Your haemoglobin (a measure of healthy red blood cells) is above a minimum level
  • Your platelet count (cells that help blood clot) is above a minimum level
  • Your creatinine kinase level (a muscle-related marker) is within an acceptable range
  • You are able and willing to come back for follow-up visits
  • You are willing to have biological samples, including DNA, stored for research
  • You are willing to use a reliable method of contraception consistently throughout the trial

Who may not be able to join:

  • You are currently suffering from an acute (sudden or short-term) illness
  • You currently have a fever above 38°C (100.4°F)
  • You are currently taking, have taken in the last 3 months, or are likely to need cholesterol-lowering medication (such as statins)
  • You have a known allergy or medical reason to avoid the study drug or any statin medications
  • You have drug-resistant TB
  • Your TB has spread outside the lungs, including to the lining around the lungs (confirm with trial site)
  • You are pregnant or planning to become pregnant in the next 6 months
  • You are unable to swallow and take oral (by mouth) medications
  • You have diabetes, as determined by specific blood sugar test results or by currently using any diabetes medication, including traditional medicines
  • You have a long-term illness or complication that could affect your safety or the trial results, such as a known chronic inflammatory condition (for example, rheumatoid arthritis or sarcoidosis)
  • You have used immune-suppressing medications (such as steroids or certain biologic drugs) within the past 2 weeks
  • You have taken part in another clinical drug trial within the past 3 months
  • You have issues with alcohol or substance use that might make it difficult to take medications regularly during the trial
  • Your doctor feels this study is not appropriate for you for any reason

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Friedrich Thienemann, MD, University of Cape Town

Phone: +27 21 406 6358

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
University of Cape Town
Registry
ClinicalTrials.gov
Start date
14 July 2020
Est. completion
30 September 2025

Where this trial is recruiting

🇿🇦 South Africa

Primary endpoints

Total lung glycolysis (TLG) on PET/CT imaging

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov